

## **Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis**

Javier Fernández<sup>1,5</sup>, Juan Acevedo<sup>2</sup>, Reiner Weist<sup>3</sup>, Thierry Gustot<sup>4</sup>, Alex Amoros<sup>5</sup>, Carme Deulofeu<sup>5</sup>, Enric Reverter<sup>1</sup>, Javier Martínez<sup>6</sup>, Faouzi Saliba<sup>7</sup>, Rajiv Jalan<sup>8</sup>, Tania Welzel<sup>9</sup>, Marco Pavesi<sup>5</sup>, María Hernández-Tejero<sup>1</sup>, Pere Ginès<sup>1,5</sup>, Vicente Arroyo<sup>5</sup> and the European Foundation for the Study of Chronic Liver Failure (EF CLIF)

<sup>1</sup>Liver ICU, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain,

<sup>2</sup> South West Liver Unit, Derriford Hospital, UK

<sup>3</sup>Department of Medicine and Surgery, Inselspital, University of Bern, Bern, Switzerland

<sup>4</sup> Liver Transplant Unit, Erasme Hospital, Brussels, Belgium,

<sup>5</sup> European Foundation for the Study of Chronic Liver Failure; EF CLIF, Barcelona, Spain

<sup>6</sup> Department of Gastroenterology and Hepatology, Hospital Ramon y Cajal, Madrid, Spain

<sup>7</sup> Centre Hépatobiliaire, Hôpital Paul Brousse, Paris, France,

<sup>8</sup> ILDH, Division of Medicine, University College London Medical School, London, United Kingdom,

<sup>9</sup> JW Goethe University, Frankfurt, Germany

**Address for correspondence:** J. Fernández, MD, PhD. Liver Unit, Hospital Clínic, Villarroel 170, 08036, Barcelona. Spain. Phone: 34-93-2275400 3329; Fax: 34-93-4515522; E-mail: [Jfdez@clinic.ub.es](mailto:Jfdez@clinic.ub.es).

**Word count:** 4463 without references

**Number of figures and tables:** 3 figures; 5 tables, 7 Supplementary tables, 3 Supplementary figures.

**Keywords:** cirrhosis; prevalence; prognosis; mortality; clinical course; immune paralysis; prophylaxis

**List of Abbreviations:** ACLF, acute-on-chronic liver failure; AD, acute decompensation; PAMPs, pathogen associated molecular patterns; DAMPs, damaged-associated molecular patterns; CANONIC, chronic liver failure (CLIF) Acute-on-Chronic Failure in Cirrhosis; SBP, spontaneous bacterial peritonitis; UTI, urinary tract infection; SSTI, skin and soft tissue infections; IA, invasive aspergillosis; MDROs, multidrug-resistant drug organisms; CDI, *Clostridium difficile* infection; HNA, human nonmercaptalbumin; ICU, intensive care unit; CLIF-C ACLFs, CLIF Consortium ACLF score; WBC: white blood cell; CRP: C reactive protein; MERKT: MER receptor tyrosine kinase

**Financial support:** The CLIF Consortium is supported by an unrestricted grant from Grifols. Rajiv Jalan is supported by a comprehensive biomedical research center, UK grant.

**Disclosures:**

*The EASL-CLIF Consortium*

It is a network of 63 European university hospitals, aimed at stimulating research on pathophysiology, diagnostic and treatment on Chronic Liver Failure. During the period 2009-2012 the EASL-CLIF Consortium had received unrestricted grants from Grifols and Gambro. Grifols has prolonged its unrestricted grant for an additional period of four years. There is no other support for the Consortium. Vicente Arroyo

(Chairman), Mauro Bernardi (Vice-Chairman), and members of the Steering Committee have no relationship with Grifols or Gambro other than conferences at international meetings (from which they may receive honorarium) or as investigators on specific projects unrelated to the Consortium. Up to now the EASL-CLIF Consortium has not performed any study promoted by pharmaceutical companies. The scientific agenda of the EASL-CLIF Consortium and the specific research protocols are made exclusively by the Steering Committee members without any participation of pharmaceutical companies.

#### *Conflicts of interest*

Rajiv Jalan received research funding from Vital Therapies, has served on Scientific Advisory Board for Conatus Pharma, and received lecture fees from Gambro and has on-going research collaboration with Gambro, Grifols and is the Principal Investigator of an Industry sponsored study (Sequana Medical). He is also inventor for a drug, L-ornithine phenyl acetate which UCL has licensed to Ocera Therapeutics. Pere Ginès has received speaker honorarium and research funding from Grifols, served on the scientific advisory board for Ferring and Sequana and received research funding from Sequana. Vicente Arroyo and Javier Fernandez have received grant and research support from Grifols. All other authors declare that they have no conflict of interest.

**Author contributions:** JF, JA, AA, CD, MP and VA participated in data analysis and interpretation. JF, JA, RW, TG, JM, ER, RJ, FS, TW, MH, PG and VA participated in the writing group. VA was responsible for obtaining funding and overall project collaboration.



## **Abstract**

Bacterial infection is a frequent trigger of ACLF, syndrome that could also increase the risk of infection. This investigation evaluated: prevalence and characteristics of bacterial and fungal infections causing and complicating ACLF; predictors of follow-up bacterial infections; and impact of bacterial infections on survival.

**Patients:** 407 patients with ACLF and 235 patients with acute decompensation (AD).

**Results:** 152 patients (37%) presented bacterial infections at ACLF diagnosis; 46% (n=117) of the remaining 255 patients with ACLF developed bacterial infections during follow-up (4 weeks). The corresponding figures in patients with AD were 25% and 18% (p<0.001). Severe infections (SBP, pneumonia, severe sepsis/shock, nosocomial infections and infections caused by multi-resistant organisms) were more prevalent in patients with ACLF. Patients with ACLF and bacterial infections (either at diagnosis or during follow-up) showed higher grade of systemic inflammation at diagnosis of the syndrome, worse clinical course (ACLF 2-3 at final assessment: 47% vs. 26%; p<0.001) and lower 90-day probability of survival (49% vs. 72.5%; p<0.001) than patients with ACLF without infection. Bacterial infections were independently associated with mortality in patients with ACLF-1 and 2. Fungal infections developed in 9 patients with ACLF (2%) and in none with AD, occurred mainly after ACLF diagnosis (78%) and had high 90-day mortality (71%).

**Conclusion:** Bacterial infections are extremely frequent in ACLF. They are severe and associated with intense systemic inflammation, poor clinical course and high mortality. Patients with ACLF are highly predisposed to develop bacterial infections within a short follow-up period and could benefit from prophylactic strategies.

**What is already known about this subject?**

Bacterial infections are a frequent precipitating event of ACLF. Type and severity of infections have been partially described. Other characteristics of bacterial infections, risk of bacterial and fungal infections after ACLF diagnosis, microbiology and relationship with clinical course are unknown.

**What are the new findings?**

- Patients with ACLF are highly predisposed to develop bacterial infections within a short follow-up period.
- Severe infections (SBP, pneumonia, severe sepsis/shock, nosocomial infections and infections caused by multi-resistant organisms) are more prevalent in patients with ACLF.
- Bacteria infections, either at diagnosis or during follow-up, are key prognostic determinants in patients with ACLF. They are associated with more severe systemic inflammation, poorer clinical course and higher mortality.
- Bacterial infections are independent predictors of 90-day mortality in patients with ACLF 1 and 2.
- Inappropriate empirical antibiotic strategies increase 90-day mortality in ACLF triggered or complicated by infection.

**Impact on clinical practice**

- Infection control practices are essential in the management of patients with ACLF.
- Patients with ACLF may benefit from prophylactic strategies aimed to decrease their prohibitive risk of infection.

## INTRODUCTION

Acute-on-chronic liver failure (ACLF) in cirrhosis is a syndrome characterized by acute decompensation (AD), organ failure(s) and high short-term mortality.<sup>1</sup> Bacterial infection is the most frequent trigger of ACLF in Western countries.<sup>1-3</sup>

Patients with decompensated cirrhosis present chronic systemic inflammation due to intestinal dysbiosis, loss of integrity of the intestinal mucosal barrier and sustained translocation of pathogen associated molecular patterns (PAMPs).<sup>4-7</sup> In patients with bacterial infections, ACLF is due to massive release of PAMPs by the infecting bacteria. PAMPs activate innate immune system leading to the release of inflammatory cytokines, vasodilatory mediators and reactive oxygen species.<sup>4,7-9</sup> Other precipitating events (i.e. acute alcoholic hepatitis; HBV flare) cause systemic inflammation by the release of damaged-associated molecular patterns (DAMPs) by the liver.<sup>10</sup> Multi-organ dysfunction/failure in ACLF develops as consequence of acute impairment in systemic circulatory function and organ hypo-perfusion and also to direct deleterious effects of inflammatory mediators in organ homeostasis, a feature known as immune-pathology.<sup>3,4,7, 11</sup>

It has been suggested that in addition to being a trigger of ACLF, bacterial infections may also be a specific complication of the syndrome. The hypothesis is that, as it occurs in sepsis,<sup>1</sup> the exaggerated systemic inflammatory response associated with ACLF may be followed by a state of immune-paralysis that predisposes to early development of secondary infections and contributes to increase mortality.<sup>12-16</sup> This hypothesis is supported by a single study showing a higher prevalence of bacterial infections during hospitalization in patients with ACLF (defined according to outdated criteria) in comparison to AD.<sup>17</sup> Other 2 studies suggest that nosocomial infections are independent predictors of ACLF.<sup>18,19</sup> Type and severity of infections were

partially described in these studies with no mention on other characteristics of bacterial infections, microbiology and relationship with clinical course.

The current study was performed to assess the prevalence of bacterial infections triggering and complicating ACLF, the characteristics of these infections and their impact on the clinical course and prognosis using information from the Canonic database.<sup>1</sup> Data on fungal infection and colonization were also analyzed.

## **PATIENTS AND METHODS**

### **Study population and aims of the study**

In the current investigation, only patients with complete 4-week follow-up data after diagnosis of AD or ACLF were included. We excluded 701 patients, 636 with AD without scheduled visits after diagnosis as per protocol and 65 with insufficient data at diagnosis (figure 1). Therefore, 642 patients were finally included, 407 with ACLF (292 diagnosed at enrolment and 115 during hospitalization) and 235 with AD without ACLF. Follow-up visits were performed at days 1, 2, 7, 14, 21 and 28 after diagnosis of ACLF or AD. Patients with AD developing ACLF during hospitalization completed the 28-day follow-up period after ACLF diagnosis. Data on the development of bacterial or fungal infections, including type and site of acquisition, clinical characteristics and microbiology, were recorded at diagnosis and at each visit.

### **Definitions related to infection**

Diagnostic criteria of bacterial infections were the following. Spontaneous bacterial peritonitis (SBP): polymorphonuclear (PMN) cell count in ascitic fluid  $\geq 250/\text{mm}^3$ . Urinary tract infection (UTI): abnormal urinary sediment ( $>10$  leukocytes/field) and



positive urinary culture or uncountable leukocytes per field if negative cultures. Spontaneous bacteremia: positive blood cultures and no cause of bacteremia. Secondary bacteremia: a) catheter-related infection (positive blood and catheter cultures), b) bacteremia occurring within 24h after an invasive procedure. Pneumonia: clinical signs of infection and new infiltrates on chest x-ray. Bronchitis: clinical features of infection, no radiographic infiltrates and positive sputum culture. Skin and soft tissue infections (SSTI): clinical signs of infection associated with swelling, erythema, heat and tenderness in the skin. Cholangitis: cholestasis, right upper quadrant pain and/or jaundice and radiological data of biliary obstruction. Spontaneous bacterial empyema: PMN count in pleural fluid  $\geq 250/\text{mm}^3$ . Secondary peritonitis: PMN count in ascitic fluid  $\geq 250/\text{mm}^3$  and evidence (abdominal CT/surgery) of an intraabdominal source of infection. *Clostridium difficile* infection (CDI): positive stool toxin in a patient with diarrhea. Unproved bacterial infection: presence of fever and leukocytosis requiring antibiotic therapy without any identifiable source.<sup>20</sup>

Fungal infections were defined as follows. Invasive candidiasis: isolation of *Candida spp* in 1 or more blood cultures (candidemia) or from normally sterile body fluids. *Candida* colonization: isolation of *Candida spp* in non-sterile fluid in the absence of infection. Probable invasive aspergillosis (IA): detection of *Aspergillus* by direct examination and/or culture of respiratory samples in the presence of radiological imaging compatible with lung infection.<sup>21</sup>

Criteria used to define the site of acquisition of infection, infection resolution and appropriateness of empirical antibiotic strategies are described in the supplementary material section.

Bacterial infections were considered as potential triggers of ACLF when they were detected prior or at the time of diagnosis of the syndrome (day 0). Infections were qualified as complications of ACLF when they were detected between day 1 and day 28 after the diagnosis of the syndrome. These criteria were based in the foreseeable sequence of events of ACLF triggered by bacterial infections. First, infections causing ACLF precede the onset of the syndrome and ACLF development frequently precedes hospital admission. Second, in the Canonic study there was an additional 1-day delay between hospital admission, study enrolment and ACLF diagnosis in all patients as per protocol design and a delay of two or more additional days in 40% of patients for other reasons<sup>1</sup>. Finally, the Canonic protocol included a complete diagnostic work-up of bacterial infections at study enrolment. The same criteria were used to qualify bacterial infections in patients with AD without ACLF.

Supplementary table 1 shows the bacteria and fungi isolated in patients with and without ACLF. Criteria used to define multidrug-resistant organism (MDROs) have been previously described.<sup>20</sup>

### **Definitions related to ACLF**

Diagnostic criteria of organ failure was based on the CLIF-C organ failure score.<sup>1,2</sup> ACLF grade 1 (ACLF-1) defines the presence of renal failure alone or of any other single organ failure if associated to renal dysfunction and/or cerebral dysfunction. ACLF grade 2 and grade 3 (ACLF-2 and 3) define the presence of 2 and 3 to 6 organ failures, respectively.<sup>1,2</sup> The clinical course of ACLF was defined as good-relatively good when the ACLF grade at final assessment was 0 or 1 and severe when it was 2 or 3.<sup>22</sup>

## **Assessment of systemic inflammation and of oxidative stress at diagnosis of ACLF and AD**

Systemic inflammation was assessed by measuring the plasma levels of five inflammatory cytokines involved in innate immune responses<sup>8</sup> and systemic oxidative stress by the determination of the redox state of human serum albumin.

Cytokines were measured using a multiplexed bead-based immunoassay on a Luminex 100 Bioanalyzer. Non-oxidized (human mercaptalbumin, HMA), and reversible and irreversible oxidized (normercaptalbumins HNA1 and HNA2) albumin forms in plasma were separated by high performance liquid chromatography and detected by fluorescence. Normal values in healthy subjects have been previously described.<sup>8</sup>

### **Statistical analysis**

Results are presented as frequencies and percentages for categorical variables, means and SDs for normally distributed continuous variables and median and interquartile range for not normally distributed continuous variables. In univariate analyses, Chi-square test was used for categorical variables, Student's t-test or ANOVA for normal continuous variables and Mann-Whitney or Kruskal Wallis test for not normally distributed continuous variables. To identify predictors of infection in ACLF patients, logistic regression models were carried out. Factors showing a clinically and statistically significant association to the outcome in univariate analyses were selected for the initial model. The final models were fitted by using a step-wise forward method based on Likelihood Ratios with the same significance level ( $p < 0.05$ ) for entering and dropping variables. The proportional-hazards model for Competing-Risks proposed by Fine and Gray<sup>23</sup> was used to identify independent predictors of

mortality. This model was chosen in order to account for liver transplantation as an event 'competing' with mortality. In all statistical analyses, significance was set at  $p < 0.05$ . Analyses were done with SPSS (version 23.0; SPSS, Inc. Chicago, IL) and SAS (version 9.4; SAS Institute Inc.; Cary, NC) statistical packages.

## RESULTS

### Overall bacterial infections

Figure 1 shows the flow chart of patients included (n=642) and excluded (n=701) from the study. A total of 360 patients (56%) presented bacterial infections during the study. In 211 patients (152 patients with ACLF and 59 with AD) infection was present at diagnosis. In the remaining 149 patients, infection was diagnosed during follow-up. Thirty-one patients with bacterial infections at diagnosis developed new bacterial infections during follow-up. Twenty-two patients with ACLF complicated by infection developed reinfection (reinfections are not included in the analysis of the results).

### Bacterial infections triggering ACLF

#### Prevalence and characteristics

Two hundred and eleven patients (33%) presented bacterial infections at diagnosis of ACLF or AD. Prevalence was significantly higher in patients with ACLF (overall infections: 37% vs. 25%; proved infections: 33.5% vs. 19%;  $p < 0.001$  each). All types of infection except for SSTI, CDI and unproved infections were more frequent in patients with ACLF. Differences were significant for pneumonia (7.7% vs. 3%,  $p=0.015$ ) and secondary peritonitis (2.6% vs. 0%,  $p=0.009$ ) (Table 1). The prevalence of infections at ACLF diagnosis was significantly higher ( $p=0.016$ ) in patients with ACLF-3 (52%; Supplementary table 2).

Progression to severe sepsis/septic shock was more frequently observed in infections present at diagnosis of ACLF than in those associated with AD (49% vs. 2%;  $p < 0.001$ ). Prevalence of nosocomial infections (53% vs. 22%;  $p < 0.001$ ) and of infections caused by MDROs (16% vs. 3%;  $p=0.01$ ) was also significantly higher in

ACLF (Table 1). Significant differences were also observed when the analysis was restricted to patients with ACLF diagnosed at enrolment (data not shown).

*Impact of infection on the severity of ACLF, clinical course and mortality*

The grade of systemic inflammation (WBC count, serum CRP levels and plasma concentration of inflammatory cytokines) was more intense in patients with infections at ACLF diagnosis than in those without (Table 2). Severity of the syndrome was also higher in patients with ACLF precipitated by bacterial infections, as indicated by a higher prevalence of encephalopathy, circulatory, respiratory and cerebral failure at diagnosis of the syndrome, a higher baseline CLIF-C ACLF score, and higher requirements of organ support during hospitalization (Table 2). Similar results were observed when patients with unproved infections were considered as non-infected (Supplementary Table 3).

The clinical course of ACLF, as estimated by the final ACLF grade, was also significantly worse in patients with ACLF caused by bacterial infections. Twenty-eight day and 90-day mortality rates were also higher in patients with ACLF triggered by bacterial infection (overall or proved episodes), differences being statistically significant only at 90 days (Table 2, Supplementary Table 3).

In order to confirm that infection-triggered ACLF portends a worse prognosis, we examined data on the 115 patients with AD who developed ACLF during follow-up. Cases triggered by infection showed higher organ support requirements, worse clinical course of ACLF and higher 28 and 90-day mortality rates than those caused by other precipitating events (Supplementary Table 4).

*Infection resolution and patient mortality according to the type and characteristics of bacterial infections detected at ACLF diagnosis.*

The resolution rate of bacterial infections detected at diagnosis was significantly lower in patients with ACLF than in those with AD (71.1% vs. 98.3%;  $p < 0.001$ ). Type of infection influenced infection resolution and mortality (Table 3). SSTI and unproved infections showed the lowest resolution rates and SSTI and SBP the highest mortality rates. The presence of severe sepsis/septic shock and the isolation of MDROs also influenced negatively infection resolution and prognosis.

**Bacterial infections complicating ACLF not triggered by infection**

*Incidence and characteristics*

Patients with ACLF not triggered by infections presented significantly higher incidence of bacterial infection during follow-up than patients with AD (46% vs. 18%,  $p < 0.001$ ) (Table 1). This feature was observed throughout the entire 28-day follow-up period (Figure 2A). The risk of developing bacterial infections correlated directly with the grade of ACLF (Figure 2B and supplementary table 2). Similar results were observed when patients with unproved infections were considered as non-infected (Supplementary Figures 1A and 1B).

All types of bacterial infections were more frequent in patients with ACLF than in patients with AD except for CDI (Table 1). Differences were statistically significant for pneumonia (8.6% vs. 1.7%,  $p < 0.001$ ), SBP (8.6% vs. 3.4%,  $p = 0.03$ ) and bacteremia (3.9% vs. 0.6%,  $p = 0.03$ ). Follow-up infections were also more severe in patients with ACLF as indicated by the higher prevalence of sepsis and severe sepsis/septic shock (41.9% vs. 6.2%,  $p < 0.001$ ) and of infections caused by MDROs (18.8% vs. 3.1%,  $p = 0.02$ ) (Table 1).

*Risk factors of follow-up bacterial infections in ACLF and impact of infection on clinical course and mortality*

Patients with ACLF developing bacterial infections during follow-up were those with higher grade of systemic inflammation and higher severity of ACLF at diagnosis as indicated by higher WBC count and higher plasma levels of CRP and cytokines, higher frequency of hepatic encephalopathy, cerebral and respiratory failure and mechanical ventilation, and higher CLIF-C ACLF score. They also presented worse clinical course and higher 28-day and 90-day mortality rates (Table 2).

Supplementary figure 2 shows the individual plasma concentrations of cytokines measured at diagnosis of the syndrome in patients with ACLF triggered by infection, ACLF complicated by infection and ACLF without infections during the whole study period. Although concentrations were higher in infected patients a marked overlap among groups was observed.

Multiple regression analysis identified CLIF-C ACLF score (n=167; OR=1.10, 95% CI=1.01-1.08; p=0.017) and HNA2 (n=68; OR=1.15, 95% CI=1.04-1.27; p<0.005) at diagnosis as independent risk factors of follow-up bacterial infections.

The resolution rate of follow-up bacterial infections in patients with ACLF was 78.6% vs. 98.8% in AD (Table 3, p<0.001). Resolution rate and mortality rates associated with bacterial infections at follow-up were not significantly influenced by the type and severity of the infections.

**Rate and characteristics of bacterial infections occurring in ACLF according to the precipitating event and the need for critical care**

Rate and characteristics of bacterial infections that triggered or complicated ACLF differed between patients hospitalized in the ICU and those admitted to the regular



ward. In contrast, type of precipitating event did not influence these parameters (Supplementary Table 5 and 6). Prevalence of infection was significantly higher in patients with ACLF triggered by infection requiring ICU admission. Pneumonia was more prevalent in critical care while UTI and SSTI were more frequent in the regular ward. As expected, severity of infection was higher in the ICU.

### **Overall impact of bacterial infections on clinical course and survival in patients with ACLF**

The clinical course (ACLF 2-3 at final assessment: 47% vs. 26%;  $p < 0.001$ ) was significantly worse and the probability of 90-d transplant-free survival significantly shorter (Figure 3A) in patients with ACLF and bacterial infection (either at diagnosis or during follow-up) than in those without (45% vs. 70%,  $p < 0.001$ ). Similar results were obtained when only patients developing proved infections were considered as infected (Supplementary Figure 3). Infections had a great impact on the prognosis of patients with the less severe forms of ACLF (Figures 3B and 3C). Infected patients with ACLF-1 and ACLF-2 showed a lower 90-d probability of survival than those without infection. In contrast, patients with ACLF-3 with and without infections did not show differences in prognosis. Patients with AD with and without bacterial infections (overall, Figure 3A, and proved, Supplementary Figure 3) also showed a similar prognosis, since patients with AD developing ACLF during hospitalization were included in the ACLF group.

Appropriateness of empirical antibiotic strategies also had an impact on clinical course and survival of patients with ACLF. Appropriate empirical antibiotic therapy was administered in 74% and 72% of bacterial infections triggering and complicating ACLF, respectively. Adequacy of initial antibiotic strategies was associated with

lower critical care requirements, better evolution of the syndrome in infection-triggered ACLF and lower 28 and 90-d mortality (Table 4).

### **Predictors of mortality**

Supplementary Table 7 shows factors associated with 90-day transplant-free mortality in the univariate and multivariate analysis in the whole series of patients with ACLF. Age (HR: 1.03), hepatic encephalopathy (HR: 1.98), serum bilirubin (HR: 1.03), INR (HR: 1.38) and serum creatinine (HR: 1.27) at diagnosis of the syndrome were identified as independent predictors of death. When the analysis was restricted to patients with ACLF-1 and 2 (Table 5, first model), serum bilirubin (HR: 1.03; 95% CI: 1.01-1.05;  $p < 0.001$ ), age (HR: 1.03; 95% CI: 1.00-1.05;  $p = 0.02$ ), bacterial infection at diagnosis or during follow-up (HR: 1.79; 95% CI: 1.08-2.96;  $p = 0.02$ ) and serum creatinine (HR: 1.14; 95% CI: 1.01-1.29;  $p = 0.04$ ) were identified as independent predictors. When appropriateness of initial antibiotic therapy was introduced in the model (Table 5, second model), this factor but not bacterial infection remained as independent predictor of survival in patients with ACLF-1 and 2 (HR: 0.40; 95% CI: 0.26-0.63;  $p < 0.001$ ). WBC count and mechanical ventilation were not entered in the regression models because of their potential collinearity with infection.

### **Fungal infection and colonization**

Fungal isolation was infrequent and mainly observed in patients with ACLF (3.9% vs. 0.4%,  $p = 0.005$ ). Of the 16 patients with ACLF and fungal isolation, seven corresponded to invasive candidiasis (5 candidemias and 2 secondary peritonitis), one to probable IA and 8 to colonization by candida. The single isolation in patients

with AD consisted of a urinary colonization by *Candida*. Six out of the eight invasive fungal infections were diagnosed during follow-up in patients with ACLF. In the remaining two patients (a secondary peritonitis and an IA) diagnosis was performed at ACLF diagnosis. Only nineteen patients (6 of them with candida colonization) received antifungal prophylaxis. Mortality rates associated with invasive fungal infection and colonization were 57% and 44% at 28-day and 71% and 67% at 90-day, respectively.

## DISCUSSION

The results of our study indicate that bacterial infection is a major problem and a key prognostic determinant in ACLF. The overall prevalence of infections in patients with ACLF was extremely high (66.1%). Two-thirds of ACLF patients presented infections at diagnosis or within follow-up. In contrast, the overall prevalence of infection in patients with AD was of 38.7%. The severity of bacterial infections, as indicated by the frequency of SBP, pneumonia, severe sepsis, nosocomial infections and infections caused by MDROs, was also significantly higher in patients with ACLF. Not surprisingly, the clinical course of ACLF, as estimated by the percentage of patients with ACLF grade 2 or 3 at final assessment, was significantly worse in patients with bacterial infections than in those without (45% vs. 25%).

The prevalence of bacterial infections at ACLF diagnosis in our series was 37.3%. These infections are important because they promote a burst of systemic inflammation that precipitates the development of the syndrome.<sup>1,3,7</sup> In the current study we compared for the first time the severity of ACLF triggered by bacterial infections and by other precipitating events. Our results clearly show a greater severity of systemic inflammation and of ACLF in patients with infections. The clinical course of ACLF was also significantly worse in these patients.

One of the most outstanding findings of our study was the extremely high incidence of follow-up bacterial infections (46%) observed in the 255 patients without infections at ACLF diagnosis. This represents that approximately one every two non-infected patients with ACLF will develop bacterial infections within 4 weeks after diagnosis. This figure contrasts sharply with the 18% incidence of follow-up infections in non-

infected patients with AD. Bacterial infections are, therefore, not only a frequent trigger of ACLF but also an extremely common complication of the syndrome.

The mechanism of this high risk of follow-up bacterial infections in patients with ACLF is likely multifactorial. Severity of systemic oxidative stress (HNA2 levels) and of ACLF (CLIF-C ACLF score) at diagnosis were significantly associated with the development of follow-up bacterial infections in the current study. Systemic inflammation may increase bacterial translocation either directly<sup>24</sup> or indirectly (by increasing circulatory dysfunction and homeostatic stimulation of sympathetic nervous system). The secondary release of norepinephrine at the intestinal mucosa impairs the local immune system function and induces qualitative and quantitative changes of the intestinal microbiota towards a phenotype associated with bacterial translocation.<sup>25</sup> The reduction of the amount of bile acid secretion secondary to liver failure is another factor favoring intestinal bacterial overgrowth.<sup>26</sup> Finally, the frequent instrumentation of patients with cerebral, respiratory or renal failure with intravenous, intra-arterial and urinary catheters and the frequent use of artificial organ support devices are other major factors increasing the rate of follow-up bacterial infections in these patients.<sup>27,28</sup> In fact, the more prevalent infections complicating ACLF were spontaneous bacteremia and spontaneous bacterial peritonitis, which are caused by bacterial translocation, and pneumonia and secondary bacteremia, which are commonly observed in patients undergoing invasive therapeutic procedures.

There are many similarities between ACLF and severe sepsis. Both conditions develop in the setting of intense systemic inflammation and oxidative stress. In patients with sepsis, systemic inflammation is initiated by an acute release of PAMPS by bacteria and secondary activation of the innate immune system cells.<sup>29-32</sup>

Approximately 40% of patients with ACLF share this pathophysiological

mechanism.<sup>1,8,33,34</sup> The second similarity is that patients with ACLF and with severe sepsis develop organ failure(s) and that this correlates closely with prognosis.<sup>1,19,32,35</sup> Finally, our study suggests that the third feature shared by patients with ACLF and with severe sepsis is that they both are highly predisposed to develop bacterial infections shortly after diagnosis. There are many evidences supporting a two-phase immune response in patients with severe sepsis.<sup>36-39</sup> Following a short initial period (few days after diagnosis) of severe systemic inflammation patients develop a second period of immune-suppression due to impairment of immune cell function and apoptotic depletion of immune cells.<sup>39</sup> During this period, aggravation of the primary infection or development of new secondary infections is common.<sup>40</sup>

The 117 non-infected patients with ACLF at diagnosis of the syndrome represent a unique population to assess if this sequence of events also occurs in ACLF, since in this group of patients the temporal relationship between systemic inflammation, ACLF development and follow-up bacterial infections is not interfered by antibiotic therapy. Our results support a two-phase clinical course in non-infected patients with ACLF. The first-phase, probably very short, is characterized by acute development of severe systemic inflammation and organ/system failure(s). ACLF is diagnosed at the end of this phase. The second-phase, of longer duration, is characterized by a remarkable high incidence of bacterial infections that mainly develop within the first week after the diagnosis of ACLF. Whether immune-suppression is involved in the pathogenesis of this second phase is currently unknown, but impaired pathogen killing activity and reactive oxygen species release by macrophages and neutrophils has been reported in these patients.<sup>41,42</sup> Recent studies have also shown that patients with ACLF have increased numbers of immunoregulatory monocytes and macrophages that express MERTK and elevated plasma levels of prostaglandin E2,

alterations that suppress the innate immune response to microbes and could increase the risk of infection.<sup>43,44</sup>

The high incidence of bacterial infection after ACLF diagnosis justifies the implementation of infection control practices such as bundles on prevention of ventilator-associated pneumonia and catheter-related bacteremia and hand hygiene.<sup>45</sup> Selective intestinal decontamination with non-absorbable antibiotics could also prevent nosocomial infections in ACLF patients but could also promote the development of MDROs.<sup>46,47</sup> Treatments aimed at restoring the patients' immune function could also be beneficial in these patients.<sup>48,49</sup> Our study also demonstrates that adequacy of empirical antibiotic strategies is also a key factor in the management of infected patients with ACLF. Inappropriate first line therapies were associated with increased mortality. Therefore, broad antibiotic schemes covering all potential pathogens should be applied at high doses within the first 48-72h after the diagnosis of infection to improve clinical efficacy and minimize the selection of resistant strains.<sup>45</sup>

We observed significantly higher mortality rate and shorter probability of survival in patients with ACLF triggered or complicated by bacterial infections than in patients with ACLF without bacterial infections throughout the entire period of observation, suggesting that bacterial infections has a major impact on the prognosis of patients with ACLF. This is also supported by the observation that infection was an independent predictor of mortality in patients with ACLF grade 1 and 2. The overall prevalence of bacterial infections in patients ACLF-3 was so high (91%) that they did not impact prognosis.

The prevalence of fungal infections in our patients with ACLF was low (2%) and mainly occurred during the follow-up period after ACLF diagnosis. This figure is in

line with recent studies showing a low incidence of invasive fungal infections in patients with cirrhosis admitted to ICU (1%).<sup>50</sup> However, fungal infections could have been under-estimated in our study since specific cultures were not performed. The relatively low rate of patients with ACLF-3 included in the Canonic series (20%) could also explain this finding.

In summary, bacterial infections are a significant problem and a major prognostic determinant in patients with ACLF. Infections are detected at ACLF diagnosis in one-third of the patients. Among the remaining patients with ACLF, approximately half develop bacterial infections within a follow-up period 4-week. The severity of systemic inflammation and of ACLF is significantly higher, the clinical course significantly worse and mortality significantly higher in patients with ACLF and bacterial infections than in those without. Adequate empirical antibiotic strategies, infection control practices and prophylactic measures are essential in the management of patients with ACLF.



## FIGURE LEGENDS

### Figure 1

Flow chart of the patients included and excluded from the study. In total, 642 patients were included. Three hundred sixty patients developed infections throughout the study: 152 with ACLF and 59 with AD presented an infection at diagnosis, 149 patients without infections at diagnosis developed infections during follow-up (117 with ACLF and 32 with AD). Finally, 53 patients with bacterial infections at diagnosis or during follow-up developed new bacterial infections.

### Figure 2A

Probability of developing bacterial infections during follow-up in patients with ACLF (red line) and AD (green line) without infections at diagnosis. Probability was significantly higher in patients with ACLF, especially in the first week after diagnosis.

### Figure 2B

Incidence of bacterial infections within follow-up in patients with AD and with ACLF-1, ACLF-2 and ACLF-3 without bacterial infections at diagnosis. Incidence correlated with the grade of ACLF, being extremely high in patients with ACLF-3.

### Figure 3A

Probability of 90-day transplant-free survival in patients with AD and ACLF with and without bacterial infections. Survival was significantly shorter ( $p < 0.001$ ) in patients with ACLF and bacterial infections [either at diagnosis (ACLF-BiD) or during follow-up (ACLF-BiFu); continuous red and orange lines, respectively] than in patients with

ACLF without bacterial infections (discontinuous red line; ACLF-NoBi) and in patients with AD with (continuous green line; AD-Bi) and without bacterial infections (discontinuous green line; AD-NoBi).

### Figure 3B

Probability of 90-d transplant-free survival in patients with ACLF-1 (green), ACLF-2 (blue) and ACLF-3 (red) with (continuous lines) and without (discontinued lines) bacterial infections (either at diagnosis or during follow-up). Patients with ACLF 1 and ACLF-2 without bacterial infections showed a higher probability of survival than those with infection ( $p=0.004$  and  $p=0.024$ , respectively).

### Figure 3C

90-d mortality rate of patients with ACLF 1-2 and with ACLF-3 with (red) and without (blue) bacterial infections (either at admission or during follow-up). Difference was statistically significant in patients with ACLF 1-2 ( $p<0.001$ ) but not in patients with ACLF-3.

## REFERENCES

1. Moreau R, Jalan R, Ginès P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome developing in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013;144:1426-37.
2. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. *J Hepatol* 2014; 61: 1038-47.
3. Arroyo V, Moreau R, Jalan R, Ginès P. Acute-on-Chronic liver failure: a new syndrome that will re-classify cirrhosis. *J Hepatol* 2015; 62: S131-S143.
4. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. *J Hepatology* 2015; 63: 1272-84.
5. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. *J Hepatol* 2014; 60: 197-209.
6. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinct features and clinical relevance. *J Hepatol* 2014; 61: 1385-1396.
7. Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, et al. Acute-on-chronic liver failure in cirrhosis. *Nat Rev Dis Primers*. 2016; Epub ahead of print.
8. Claria J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. *Hepatology*. 2016;64:1249-64.
9. Gandoura S, Weiss E, Ratou PE, Fassen M, Gustot T, Lemoine F, et al. Gene and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. *J Hepatol* 2013;58:936–948.
10. Kubes P, Mehal WZ. Sterile inflammation in the liver. *Gastroenterology* 2012; 143:

1158-1172.

11. Cohen J. The immunopathogenesis of sepsis. *Nature* 2002;420:885–891.
12. Delano MJ, Ward PA. The immune system's role in sepsis progression, resolution, and long-term outcome. *Immunol Rev* 2016;274:330-353.
13. Malik R, Mookerjee RP, Jalan R. Infection and inflammation in liver failure: two sides of the same coin. *J Hepatol* 2009;51:426–429.
14. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on-chronic liver failure. *J Hepatol* 2012;57:1336-48.
15. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. *J Hepatol* 2005;42:195-201.
16. Bernsmeier C, Pop OT, Singanayagam A, Triantafyllou E, Patel VC, Weston CJ, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. *Gastroenterology* 2015;148:603-615.
17. Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. *Gut*. 2010;59:1561-9.
18. Sargenti K, Prytz H, Nilsson E, Kalaitzakis E. Predictors of mortality among patients with compensated and decompensated liver cirrhosis: the role of bacterial infections and infection-related acute-on-chronic liver failure. *Scand J Gastroenterol* 2015;50:875-83.
19. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. *Hepatology* 2014;60:250-6.

20. Fernández J, Acevedo J, Prado V, Mercado M, Castro M, Pavesi M, et al. Clinical course and short-term mortality of cirrhotic patients with infections other than spontaneous bacterial peritonitis. *Liver Int.* 2016. Epub ahead of print.
21. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis.* 2008;46:1813–182.
22. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. *Hepatology* 2015;62:243-52
23. Fine JPJ, Gray RJ, Grey R. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc* 1999;94:496-509.
24. Hietbrink F, Besselink MG, Renooij W, de Smet MB, Draisma A, van der Hoeven H, Pickkers P. Systemic inflammation increases intestinal permeability during experimental human endotoxemia. *Shock* 2009;32:374-8.
25. Worlicek M, Knebel K, Linde HJ, Moleda L, Schölmerich J, Straub RH, et al. Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis. *Gut* 2010;59:1127–1134.
26. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. *Proc Natl Acad Sci U S A.* 2006;103:3920-5.
27. Eggimann P, Pittet D. Infection control in the ICU. *Chest* 2001;120:2059-93.

28. Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodes J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. *Hepatology* 2002;35:140-148.
29. Kragstbjerg P, Holmberg H, Vikerfors T. Dynamics of blood cytokine concentrations in patients with bacteremic infections. *Scand J Infect Dis* 1996;28:391-8.
30. Casey LC<sup>1</sup>, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. *Ann Intern Med* 1993;119:771-8.
31. Pinsky MR<sup>1</sup>, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. *Chest* 1993;103:565-75.
32. Gustot T. Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response. *Curr Opin Crit Care* 2011;2:153-9.
33. Shi Y, Yang Y, Hu Y, Wu W, Yang Q, Zheng M, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. *Hepatology* 2015; 62: 232-242.
34. Michelena J, Altamirano J, Abrales JG, Affò S, Morales-Ibanez O, Sancho-Bru P, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. *Hepatology* 2015;62:762-72.
35. Abraham E., Singer M. Mechanisms of sepsis-induced organ dysfunction. *Crit. Care Med.* 2007;35:2408–2416.
36. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. *N Engl J Med* 2003, 348:138-150.
37. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. *Crit Care Med* 1996, 24:1125-1128.

38. Hotchkiss RS, Opal S: Immunotherapy for sepsis a new approach against an ancient foe. *N Engl J Med* 2010, 363:87-89.
39. Patil NK, Bohannon JK, Sherwood ER. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression. *Pharmacol Res.* 2016;111:688-702.
40. Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. *Crit Care* 2011;15:R183.
41. Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. *J Hepatol* 2007; 46:816-26.
42. Antoniadou CG, Wendon J, Vergani D. Paralyzed monocytes in acute on chronic liver disease. *J Hepatol* 2005; 42:163-5.
43. Bernsmeier C, Pop OT, Singanayagam A, Triantafyllou E, Patel VC, Weston CJ, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. *Gastroenterology* 2015;148:603-615.
44. O'Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. *Nat Med* 2014;20:518-23.
45. Fernandez J, Tandon P, Mensa J, Garcia-Tsao G. Antibiotic prophylaxis in cirrhosis: good or bad. *Hepatology* 2016; 63:2019-31.
46. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. *N Engl J Med* 2009;360:20-31.

47. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH; SuDDICU Canadian Study Group. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. *Lancet Infect Dis* 2013;13:328-41.
48. Bernsmeier C, Singanayagam A, Patel VC, Wendon J, Antoniadou CG. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure. *Immunotherapy* 2015;7:641-54.
49. Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, et al. Granulocyte colony-stimulating factor mobilizes CD34 (+) cells and improves survival of patients with acute-on-chronic liver failure. *Gastroenterology* 2012;142:505-512.
50. Theocharidou E, Agarwal B, Jeffrey G, Jalan R, Harrison D, Burroughs AK, Kibbler CC. Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit. *Clin Microbiol Infect* 2016;22:189.e1-7.





**Table 1. Prevalence and characteristics of bacterial infections present at diagnosis or developed during follow-up and associated mortality in patients with AD and ACLF**

|  | At diagnosis* |                 | During follow-up** |                 |
|--|---------------|-----------------|--------------------|-----------------|
|  | AD<br>(n=235) | ACLF<br>(n=407) | AD<br>(n=176)      | ACLF<br>(n=255) |
| <b>Prevalence and types of infection</b>       |               |                 |                    |                 |
| <i>Prevalence of infections (n/%)</i>          | 59(25.1)      | 152(37.3)***    | 32(18.2)           | 117(45.9)***    |
| <i>Types of infection (n/%)</i>                |               |                 |                    |                 |
| Spontaneous bacterial peritonitis              | 16(6.8)       | 41(9.8)         | 6(3.4)             | 22(8.6)*        |
| Urinary infections                             | 10(4.3)       | 25(6.0)         | 12(6.8)            | 27(10.6)        |
| Pneumonia                                      | 7(3.0)        | 32(7.7)*        | 3(1.7)             | 22(8.6)***      |
| Unproved infections                            | 14(6.0)       | 16(3.8)         | 7(4.0)             | 18(7.0)         |
| SSTI   | 7(3.0)        | 12(2.9)         | 1(0.6)             | 7(2.7)          |
| Spontaneous/secondary bacteraemia              | 1(0.4)        | 9(2.2)          | 1(0.6)             | 10(3.9)*        |
| Secondary bacterial peritonitis                | -             | 11(2.6)**       | -                  | 2(0.8)          |
| Other <sup>1</sup>                             | 3(1.3)        | 6(1.4)          | 1(0.6)             | 8(3.1)          |
| <i>Clostridium difficile</i> infection         | 1(0.4)        | -               | 1(0.6)             | 1(0.4)          |
| <b>Characteristics of bacterial infections</b> |               |                 |                    |                 |
| <i>Site of acquisition (n/%)</i>               |               |                 |                    |                 |
| Community-acquired                             | 32(54.2)      | 38(25.0)***     | -                  | -               |
| Healthcare-associated                          | 14(23.7)      | 34(22.4)        | -                  | -               |
| Nosocomial                                     | 13(22.0)      | 80(52.6)        | 32(100.0)          | 117(100.0)      |
| <i>Infections caused by MDROs (n/%)</i>        |               |                 |                    |                 |
| No   | 57(96.6)      | 128(84.2)*      | 31(96.9)           | 95(81.2)*       |
| Yes  | 2(3.4)        | 24(15.8)        | 1(3.1)             | 22(18.8)        |
| <i>Sepsis (n/%)</i>                            |               |                 |                    |                 |
| No sepsis                                      | 46(78.0)      | 78(51.3)***     | 30(93.8)           | 68(58.1)***     |
| Sepsis   | 12(20.3)      | -               | 1(3.1)             | 26(22.2)        |
| Severe sepsis or shock                         | 1(1.7)        | 74(48.7)        | 1(3.1)             | 23(19.7)        |
| <b>Mortality (n/%)</b>                         |               |                 |                    |                 |
| 28-day mortality                               | 1(1.7)        | 54(35.5)***     | 2(6.3)             | 45(38.5)***     |
| 90-day mortality                               | 6(10.2)       | 77(50.7)***     | 3(9.4)             | 60(51.3)***     |

\*All patients included

\*\*Only patients without bacterial infections at diagnosis

SSTI Skin and soft tissue infections ; MDROs: Multidrug resistant organisms

<sup>1</sup> Other infections at diagnosis of ACLF: tracheobronchitis (4), spontaneous bacterial empyema (n=1), cholangitis (1), undefined (3). Other infections during follow-up: dental infection (1), undefined (8)

\*p-value<0.05; \*\*p-value<0.01; \*\*\*p-value<0.001

**Table 2. Clinical and laboratory data at ACLF diagnosis, clinical course, and mortality in patients with and without bacterial infection at diagnosis or during follow-up#**

|   | Bacterial infection at ACLF diagnosis (n=152) | No bacterial infection at ACLF diagnosis (n=255) | Bacterial infection during follow-up## (n=117) | No bacterial infection during follow-up## (n=138) |
|---|---|--|--|---|
| <b>Cause of admission</b>               |   |  |  |   |
| GI bleeding                             | 7(8.3)  | 26(19.7)*  | 14(21.2)                                       | 12(18.2)  |
| Infection                               | 31(36.9)                                      | 25(18.9)**                                       | 16(24.2)                                       | 9(13.6)   |
| Encephalopathy                          | 10(11.9)                                      | 33(25.0)*  | 20(30.3)                                       | 13(19.7)  |
| HRS                                     | 2(2.4)  | 7(5.3)   | 2(3.0)   | 5(7.6)  |
| Ascites                                 | 19(22.6)                                      | 27(20.5)   | 9(13.6)  | 18(27.3)  |
| Other                                   | 15(17.9)                                      | 14(10.6)   | 5(7.6)   | 9(13.6)   |
| <b>Clinical and laboratory data</b>     |   |  |  |   |
| Age (years)                             | 56±13   | 56±11  | 54±11  | 57±11*  |
| Alcoholic cirrhosis (%)                 | 80(53.7)                                      | 148(61.4)  | 63(57.8)                                       | 85(64.4)  |
| No prior decompensation (%)             | 43(29.7)                                      | 53(22.3)   | 25(22.3)                                       | 28(22.2)  |
| Ascites with surrogates (%)             | 147(96.7)                                     | 252(98.8)  | 116(99.2)                                      | 136(98.6)   |
| Encephalopathy (%)                      | 83(61.0)                                      | 111(50.2)*                                       | 62(60.8)                                       | 49(41.2)**  |
| WBC (x10 <sup>9</sup> /L)               | 9.9(6.1-15.4)                                 | 6.8(4.6-11.7)***                                 | 7.5(5.0-13.2)                                  | 6.5(4.6-9.9)*                                     |
| Serum CRP (mg/L)                        | 36(21-77)                                     | 25(11-46)***                                     | 29(16-51)                                      | 19(9-40)*   |
| Serum bilirubin (mg/dL)                 | 6.8(3.3-14.6)                                 | 8.5(2.6-19.4)                                    | 11.0(2.7-22)                                   | 6.6(2.5-16.5)                                     |
| INR                                     | 1.9(1.5-2.7)                                  | 1.9(1.4-2.6)                                     | 2.0(1.5-2.5)                                   | 1.8(1.4-2.6)                                      |
| Serum creatinine (mg/dL)                | 1.7(1.0-2.6)                                  | 1.9(1.0-2.6)                                     | 1.9(1.1-3.0)                                   | 1.8(0.9-2.4)                                      |
| Plasma sodium (mEq/L)                   | 134±7   | 135±6  | 135±6  | 134±6   |
| Serum albumin                           | 2.8(2.4-3.2)                                  | 2.9(2.5-3.4)                                     | 2.9(2.6-3.3)                                   | 2.9(2.5-3.5)                                      |
| Renal failure (%)                       | 72(52.2)                                      | 112(50.9)  | 52(51.5)                                       | 60(50.4)  |
| Cerebral failure (%)                    | 42(30.9)                                      | 38(17.2)**                                       | 24(23.3)                                       | 14(11.9)*   |
| Respiratory failure (%)                 | 25(20.5)                                      | 18(10.2)*  | 13(15.7)                                       | 5(5.4)*   |
| Circulatory failure (%)                 | 45(34.1)                                      | 39(18.0)***                                      | 22(22.2)                                       | 17(14.4)  |
| Coagulation failure (%)                 | 52(39.1)                                      | 65(30.5)   | 27(27.6)                                       | 38(33.0)  |
| Liver failure (%)                       | 48(35.0)                                      | 93(42.9)   | 46(46.0)                                       | 47(40.2)  |
| MELD score                              | 28±7  | 27±7   | 28±7   | 27±7  |
| CLIF-C ACLF score                       | 54±11   | 48±9**   | 50±9   | 46±9*   |
| NASCELD criteria for ACLF\$             | 22(14.5)                                      | 22(8.6)  | 17(14.5)                                       | 5(3.6)**  |
| ACLF-1(%)                               | 71(46.7)                                      | 133(52.2)  | 50(42.7)                                       | 83(60.1)***                                       |
| ACLF-2(%)                               | 52(34.2)                                      | 95(37.3)   | 45(38.5)                                       | 50(36.2)  |
| ACLF-3(%)                               | 29(19.1)                                      | 27(10.6)   | 22(18.8)                                       | 5(3.6)  |
| <b>Inflammatory cytokines</b>           |   |  |  |   |
| TNF (pg/ml)                             | 37(26-50)                                     | 29(17-39)**                                      | 31(18-42)                                      | 25(15-35)*  |
| IL-6 (pg/ml)                            | 101(34-466)                                   | 29(13-75)***                                     | 33(16-100)                                     | 26(11-43)*  |
| IL-8 (pg/ml)                            | 117(66-225)                                   | 75(38-165)**                                     | 87(45-165)                                     | 60(32-169)  |
| IL-10 (pg/ml)                           | 18(7-58)                                      | 6(2-19)***                                       | 7(3-34)  | 4(1-14)**   |
| IL-1ra (pg/ml)                          | 39(14-108)                                    | 16(8-42)**                                       | 23(9-57)                                       | 14(7-30)*   |
| <b>Albumin oxidation fractions&amp;</b> |   |  |  |   |
| HMA (%)                                 | 42(30-58)                                     | 46(34-58)  | 42(33-58)                                      | 48(35-56)   |
| HNA1+HNA2 (%)                           | 56(42-68)                                     | 52(41-64)  | 51(41-65)                                      | 52(43-64)   |
| HNA2 (%)                                | 11(8-15)                                      | 11(6-15)   | 12(7-17)                                       | 8(5-12)*  |
| <b>Need for critical care (28-d)</b>    |   |  |  |   |
| ICU                                     | 95(62.5)                                      | 112(43.9)***                                     | 66(56.4)                                       | 46(33.3)***                                       |
| Mechanical ventilation                  | 58(38.2)                                      | 56(22.0)***                                      | 41(35.0)                                       | 15(10.9)***                                       |
| Renal replacement therapy               | 51(33.6)                                      | 55(21.6)**                                       | 31(26.5)                                       | 24(17.4)  |
| NASCELD criteria for ACLF\$             | 63(41.5)                                      | 63(24.7)***                                      | 46(39.3)                                       | 17(12.3)***                                       |
| <b>Clinical course of ACLF</b>          |   |  |  |   |
| No ACLF or ACLF-1 at final assessment   | 74(51.0)                                      | 151(64.8)**                                      | 61(54.5)                                       | 90(74.4)**  |
| ACLF 2-3 at final assessment            | 71(49.0)                                      | 82(35.2)   | 51(45.5)                                       | 31(25.6)  |
| <b>28-day transplant free mortality</b> |   |  |  |   |
|   | 54(35.5)                                      | 71(27.8)   | 45(38.5)                                       | 26(18.8)***                                       |
| <b>90-day transplant free mortality</b> |   |  |  |   |
|   | 77(50.7)                                      | 98(38.4)*  | 60(51.3)                                       | 38(27.5)***                                       |

# Patients are divided in two groups: A: patients with and without bacterial infections at diagnosis of ACLF, B: patients with ACLF without bacterial infections at diagnosis who did and did not develop bacterial infections during follow-up.

## Patients with ACLF and bacterial infection at diagnosis of the syndrome were excluded from this analysis

\$: two or more of the following: vasopressors, renal replacement therapy, mechanical ventilation, grade 3-4 hepatic encephalopathy  
& According to the redox state at cysteine 34  
\*P-value<0.05; \*\*P-value<0.01; \*\*\*P-value<0.001

**Table 3. Type and characteristics of bacterial infections at ACLF diagnosis or during follow-up: relationship with infection resolution and patient mortality**

|   | Patients with bacterial infections at ACLF diagnosis |                 |                      |                      | Patients with bacterial infections during follow-up |                 |                      |                      |
|---|--|-----------------|----------------------|----------------------|---|-----------------|----------------------|----------------------|
|   | N  | Resolution Rate | Mortality at 28 days | Mortality at 90 days | N   | Resolution Rate | Mortality at 28 days | Mortality at 90 days |
| <b>Prevalence and types of infection</b>        |  |                 |                      |                      |   |                 |                      |                      |
| <i>Prevalence of bacterial infections (n/%)</i> | 152  | 108(71.1)       | 54(35.5)             | 77(50.7)             | 117   | 92(78.6)        | 45(38.5)             | 60(51.3)             |
| <i>Type of Infections (n/%)</i>                 |  |                 |                      |                      |   |                 |                      |                      |
| Spontaneous bacterial peritonitis               | 41   | 26(63.4)**      | 19(46.3)             | 24(58.5)*            | 22  | 16(72.7)        | 10(45.5)             | 13(59.1)             |
| Urinary infections                              | 25   | 24(96.0)        | 5(20.0)              | 11(44.0)             | 27  | 23(85.2)        | 8(29.6)              | 11(40.7)             |
| Pneumonia                                       | 32   | 20(62.5)        | 12(37.5)             | 18(56.3)             | 22  | 15(68.2)        | 12(54.6)             | 14(63.6)             |
| Unproved infections                             | 16   | 9(56.3)         | 7(43.8)              | 8(50.0)              | 18  | 16(88.9)        | 11(61.1)             | 12(66.7)             |
| SSTI  | 12   | 6(50.0)         | 7(58.3)              | 9(75.0)              | 7   | 6(85.7)         | 0(0.0)               | 1(14.3)              |
| Spontaneous/secondary bacteraemia               | 9  | 7(77.8)         | 2(22.2)              | 3(33.3)              | 10  | 8(80.0)         | 2(20.0)              | 5(50.0)              |
| Secondary bacterial peritonitis                 | 11   | 10(90.9)        | 2(18.2)              | 4(36.5)              | 2   | 0(0.0)          | 1(50.0)              | 2(100.0)             |
| Other <sup>1</sup>                              | 6  | 6(100.0)        | 0(0.0)               | 0(0.0)               | 8   | 7(87.5)         | 1(12.5)              | 2(25.0)              |
| <i>Clostridium difficile</i> infection          | 0  | -               | -                    | -                    | 1   | 1(100.0)        | 0(0.0)               | 0(0.0)               |
| <b>Characteristics of bacterial infection</b>   |  |                 |                      |                      |   |                 |                      |                      |
| <i>Site of acquisition (n/%)</i>                |  |                 |                      |                      |   |                 |                      |                      |
| Community-acquired                              | 38   | 27(71.1)        | 15(39.5)             | 16(42.1)             | -   | -               | -                    | -                    |
| Healthcare-associated                           | 34   | 20(58.8)        | 14(41.2)             | 19(55.9)             | -   | -               | -                    | -                    |
| Nosocomial                                      | 80   | 61(76.3)        | 25(31.3)             | 42(52.5)             | 117   | 92(78.6)        | 45(38.5)             | 60(51.3)             |
| <i>Multiresistant bacterial infection (n/%)</i> |  |                 |                      |                      |   |                 |                      |                      |
| No  | 128  | 94(73.4)        | 43(33.6)             | 60(46.9)*            | 95  | 77(81.1)        | 36(37.9)             | 47(49.5)             |
| Yes   | 24   | 14(58.3)        | 11(45.8)             | 17(70.8)             | 22  | 15(68.2)        | 9(40.9)              | 13(59.1)             |
| <i>Severity of infection (n/%)</i>              |  |                 |                      |                      |   |                 |                      |                      |
| No sepsis                                       | 78   | 63(80.8)**      | 23(29.5)             | 37(47.4)             | 68  | 51(75.0)        | 23(33.8)             | 31(45.6)             |
| Sepsis  | 0  | 0(0.0)          | 0(0.0)               | 0(0.0)               | 26  | 20(76.9)        | 10(38.5)             | 15(57.7)             |
| Severe sepsis or shock                          | 74   | 45(60.8)        | 31(41.9)             | 40(54.1)             | 23  | 15(65.2)        | 12(52.2)             | 14(60.9)             |

SSTI Skin and soft tissue infections <sup>1</sup> Other infections at diagnosis of ACLF: tracheobronchitis (4), spontaneous bacterial empyema (n=1), cholangitis (1), undefined (3).

Other infections during follow-up: dental infection (1), undefined (8)

\*p-value<0.05; \*\*p-value<0.01; \*\*\*p-value<0.001

**Table 4. Clinical course and mortality of patients with ACLF triggered or complicated by infection receiving appropriate or inappropriate empirical antibiotic treatment#**

|   | Bacterial infection at ACLF diagnosis (n=152)       |  | Bacterial infection during follow-up## (n=117)      |   |
|---|---|--|---|---|
|   | Inappropriate empirical antibiotic treatment (n=35) | Appropriate empirical antibiotic treatment (n=112) | Inappropriate empirical antibiotic treatment (n=24) | Appropriate empirical antibiotic treatment (n=84) |
| <b>ICU admission and organ support</b>  |   |  |   |   |
| ICU                                     | 26(74.3)  | 68(60.7)   | 18(75.0)  | 42(50.0)*   |
| Mechanical ventilation                  | 17(48.6)  | 40(35.7)   | 10(41.7)  | 28(33.3)  |
| Renal replacement therapy               | 15(42.9)  | 35(31.3)   | 7(29.2)   | 20(23.8)  |
| <b>ACLF evolution</b>                   |   |  |   |   |
| No ACLF or ACLF-1 at final assessment   | 12(35.3)  | 59(55.1)*  | 12(54.6)  | 47(57.3)  |
| ACLF 2-3 at final assessment            | 22(64.7)  | 48(44.9)   | 10(45.4)  | 35(42.7)  |
| <b>28-day transplant free mortality</b> | 19(54.3)  | 32(28.6)**   | 11(45.8)  | 26(31.0)  |
| <b>90-day transplant free mortality</b> | 26(74.3)  | 47(42.0)***  | 16(66.7)  | 36(42.9)*   |

# According to microbiological results or the need for escalation of initial antibiotic treatments in culture negative infections. Data on empirical antibiotic therapy were not available in 14 patients.

## Patients with ACLF and bacterial infection at diagnosis of the syndrome were excluded from this analysis

\*P-value<0.05; \*\*P-value<0.01; \*\*\*P-value<0.001

**Table 5. Predictors of 90-day mortality in the univariate and multivariate analysis in patients with ACLF 1 and ACLF 2.****Model 1. Without considering appropriateness of empirical antibiotic therapy**

| Predictors  | Univariate Analysis |         | Multivariate analysis# |         |
|---|---------------------|---------|------------------------|---------|
|   | HR (CI 95%)         | p-value | HR (CI 95%)            | p-value |
| Infection (at ACLF diagnosis or during follow-up) | 1.65(1.05-2.60)     | 0.031   | 1.79(1.08-2.96)        | 0.023   |
| Age (years)                                       | 1.01(0.99-1.03)     | 0.147   | 1.03(1.00-1.05)        | 0.018   |
| Encephalopathy (%)*                               | 1.56(1.03-2.37)     | 0.036   | -                      | -       |
| Leukocytes (x10 <sup>9</sup> /L)*                 | 1.07(1.04-1.11)     | <0.001  | -                      | -       |
| Bilirubin (mg/dL)*                                | 1.02(1.01-1.04)     | 0.007   | 1.03(1.01-1.05)        | <0.001  |
| INR*  | 1.11(0.91-1.36)     | 0.299   | -                      | -       |
| Creatinine (mg/dL)*                               | 1.12(0.98-1.28)     | 0.098   | 1.14(1.01-1.29)        | 0.041   |
| Heart rate (b.p.m)*                               | 1.02(1.01-1.03)     | 0.001   | -                      | -       |
| Mechanical ventilation**                          | 2.55(1.62-4.01)     | <0.001  | -                      | -       |
| Renal replacement therapy**                       | 2.32(1.51-3.57)     | <0.001  | -                      | -       |

**Model 2. Considering appropriateness of empirical antibiotic therapy**

|   |                 |        |                 |        |
|---|-----------------|--------|-----------------|--------|
| Infection (at ACLF diagnosis or during follow-up) | 1.65(1.05-2.60) | 0.031  | 1.99(0.65-6.10) | 0.228  |
| Appropriate empirical antibiotic therapy          | 0.41(0.27-0.62) | <0.001 | 0.40(0.26-0.63) | <0.001 |
| Age (years)                                       | 1.01(0.99-1.03) | 0.147  | 1.02(1.00-1.04) | 0.037  |
| Encephalopathy (%)*                               | 1.56(1.03-2.37) | 0.036  | -               | -      |
| Leukocytes (x10 <sup>9</sup> /L)*                 | 1.07(1.04-1.11) | <0.001 | -               | -      |
| Bilirubin (mg/dL)*                                | 1.02(1.01-1.04) | 0.007  | 1.03(1.01-1.05) | 0.009  |
| INR*  | 1.11(0.91-1.36) | 0.299  | -               | -      |
| Creatinine (mg/dL)*                               | 1.12(0.98-1.28) | 0.098  | -               | -      |
| Heart rate (b.p.m)*                               | 1.02(1.01-1.03) | 0.001  | -               | -      |
| Mechanical ventilation**                          | 2.55(1.62-4.01) | <0.001 | -               | -      |
| Renal replacement therapy**                       | 2.32(1.51-3.57) | <0.001 | -               | -      |

\* At ACLF diagnosis; \*\* Within the 4-weeks follow-up period

#Mechanical ventilation and leukocytes were not included in the multivariate model because of potential collinearity with infection

FIGURE 1






FIGURE 2A




FIGURE 2B




FIGURE 3A




FIGURE 38




FIGURE 3C

